Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen is planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial showed promise, the drugmaker said.

Biogen to seek US approval for Alzheimer's drug, sending shares soaring 34%

Shares of Biogen Inc. BIIB, +1.57% rocketed 35% in premarket trading Tuesday, after the biotechnology company reported third-quarter profit and revenue that beat expectations and said it would pursue regulatory approval of its Alzheimer's treatment.

Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process

Biogen BIIB, +1.57% said it will pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease after consulting with the U.S.

Biogen says it will pursue FDA approval of early Alzheimer's drug

New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

CAMBRIDGE, Mass. and INCHEON, Korea, Oct.  21, 2019  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis today announced that they will present new real-world data from the companies’ anti-TNF biosimilar portfolio, which includes FLIXABI™ (infliximab) and IMRALDI™ (adalimumab). These data, which provide further insight into the long-term safety and efficacy as well as patient experience with anti-TNF biosimilars, are being presented at United European Gastroenterology (UEG) Week 2019 taking place in Barcelona, Spain (October 19-23).

Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week

Intel

JPMorgan Chase & Co

Toronto-Dominion Bank

Wells Fargo

According to the GuruFocus All-In-One Screener, the following companies have grown their book value per share over the past decade.

5 Bargain Stocks Boosting Book Value

Regeneron Pharmaceuticals

Biogen and Regeneron Pharmaceuticals are most likely among large-cap biotech companies to top Wall Street's third-quarter sales and earnings expectations, an analyst said Friday.

Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off

Gilead Sciences

Which of these two biotech titans is the better buy right now?

Better Buy: Biogen vs Gilead Sciences

Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space.

Biogen Strengthens MS & SMA Portfolio as Competition Lurks

CAMBRIDGE, Mass., Oct.  02, 2019  (GLOBE NEWSWIRE) --  Biogen Inc.  (Nasdaq: BIIB) today announced that the journal Neuromuscular Disorders has published data from NURTURE, the first study investigating a treatment targeting the underlying cause of spinal muscular atrophy (SMA) in infants treated pre-symptomatically. Data from the NURTURE study demonstrated that infants who initiated treatment with SPINRAZA prior to the onset of clinical symptoms attained unparalleled results compared to the natural history of the disease. As of March 2019 all participants were alive, without the need for permanent ventilation and experienced continuous improvements with the majority achieving motor milestones in timelines consistent with normal development. The results also demonstrated durability of effect with children making progress throughout the study. 

Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

Biogen stock lost nearly 30% of its value in mid-March when the biotech company scrapped two studies of a late-stage Alzheimer’s treatment. Is now time to invest in Biogen stock?

Biogen Stock Flailed On Alzheimer's Flop — Is This Biotech Stock A Buy Now?

Biogen Inc. BIIB, +1.13% said Tuesday it has named Dr. Alfred Sandrock as executive vice president of research and development, a role he will take on alongside his current role of chief medical officer.

Biogen names Alfred Sandrock EVP of R&D, replacing Michael Ehlers who is leaving company

Amgen

Which stock wins in a battle between these two big biotechs?

Better Buy: Biogen (BIIB) vs. Amgen (AMGN)

Novartis

Biogen is initiating a new Phase III trial for Spinraza in adult-onset SMA.

New Biogen Spinraza Trial Has Little To Do With Novartis Competition

Moderna

Telesis Bio Inc

Unfilled promises by biotechs can lead to broken hearts for investors.

Messenger RNA Is Just the Latest Siren Song From Biotech: Don’t Listen

Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex

Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy

CAMBRIDGE, Mass., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP), part of the of the European Medicines Agency (EMA), recommended an update to marketing authorizations of approved interferon beta treatments, including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), to remove pregnancy contraindications and, where clinically needed, to allow use during pregnancy and breastfeeding in women with relapsing multiple sclerosis (MS).

Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.

Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

CAMBRIDGE, Mass., Sept.  18, 2019  (GLOBE NEWSWIRE) --  Biogen Inc.  (Nasdaq: BIIB) today announced updates to the SPINRAZA (nusinersen) clinical development program including the initiation of a new global clinical trial, DEVOTE. The DEVOTE study will evaluate if a higher dose of SPINRAZA can provide even greater efficacy in the treatment of spinal muscular atrophy (SMA) across a broad patient population. In addition, new data further demonstrating the safety and efficacy of treatment with SPINRAZA in individuals with later-onset SMA will be featured in a podium presentation at the 13th Congress of the European Paediatric Neurology Society (EPNS) in Athens (September 17-21).

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

CAMBRIDGE, Mass., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI World) for the fourth time, after being the first U.S.-based biotech company to ever make the list in 2013.

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.

Biogen Stops Late-Stage Studies on Alzheimer's Candidate

Biogen stock popped in relief Friday after the biotech company scrapped several tests in Alzheimer's treatment for a drug known as elenbecestat. It was being developed with Japan's Eisai.

Biogen Scraps 2 More Studies In Alzheimer's Disease — And Shares Pop

Casey's General Stores

Clean Harbors

Crocs

From ECB stimulus to trade optimism, all are helping stocks eke out gains. And let's admit that recession may be coming, but it isn't around the corner.

What September Doldrums? Here's Why Stocks Are Moving Higher

Shares of Biogen Inc. BIBB, -1.96% fell 1.6% in premarket trading Friday, after the the biotechnology company and Tokyo-based Eisai Co.

Biogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatment

CBRE Group

International Consolidated Airlines Group SA

KLA-Tencor

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

News for Biogen Stock (BIIB)